| Target Price | €43.31 |
| Price | €38.99 |
| Potential | 11.09% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €43.31. This is 11.09% higher than the current stock price. The highest price target is €50.83 30.37% , the lowest is €38.60 1.00% . | |
| A rating was issued by 24 analysts: 12 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 11.09% . Most analysts recommend the Qiagen stock at Buy or hold. |
25 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 2.28% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 5.77% , the lowest is €1.7b 3.78% .
This results in the following potential growth metrics:
| 2024 | €1.7b | 0.66% |
|---|---|---|
| 2025 | €1.8b | 7.07% |
| 2026 | €1.9b | 6.14% |
| 2027 | €2.0b | 6.27% |
| 2028 | €2.2b | 10.38% |
| 2029 | €2.4b | 7.93% |
| 2030 | €2.8b | 17.88% |
22 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €663m . This is 37.93% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €738m 53.19% , the lowest is €576m 19.69% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | €429m | 10.64% |
|---|---|---|
| 2025 | €663m | 55.02% |
| 2026 | €710m | 6.98% |
| 2027 | €774m | 9.01% |
| 2028 | €837m | 8.14% |
| 2029 | €884m | 5.64% |
| 2024 | 25.51% | 9.92% |
|---|---|---|
| 2025 | 36.93% | 44.79% |
| 2026 | 37.22% | 0.79% |
| 2027 | 38.18% | 2.58% |
| 2028 | 37.40% | 2.04% |
| 2029 | 36.61% | 2.11% |
25 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €443m . This is 28.86% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €460m 33.51% , the lowest is €424m 23.04% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | €71.0m | 75.51% |
|---|---|---|
| 2025 | €443m | 524.83% |
| 2026 | €477m | 7.58% |
| 2027 | €523m | 9.65% |
| 2028 | €585m | 12.00% |
| 2029 | €645m | 10.11% |
| 2024 | 4.23% | 75.67% |
|---|---|---|
| 2025 | 24.66% | 483.55% |
| 2026 | 25.00% | 1.38% |
| 2027 | 25.79% | 3.16% |
| 2028 | 26.17% | 1.47% |
| 2029 | 26.70% | 2.03% |
25 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.04 . This is 30.77% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.12 35.90% , the lowest is €1.95 25.00% .
This results in the following potential growth metrics and future valuations:
| 2024 | €0.32 | 75.38% |
|---|---|---|
| 2025 | €2.04 | 537.50% |
| 2026 | €2.20 | 7.84% |
| 2027 | €2.41 | 9.55% |
| 2028 | €2.70 | 12.03% |
| 2029 | €2.97 | 10.00% |
| Current | 24.99 | 79.61% |
|---|---|---|
| 2025 | 19.08 | 23.66% |
| 2026 | 17.74 | 7.02% |
| 2027 | 16.18 | 8.79% |
| 2028 | 14.44 | 10.75% |
| 2029 | 13.12 | 9.14% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.86 and an P/S ratio of 4.66 .
This results in the following potential growth metrics and future valuations:
| Current | 4.97 | 13.26% |
|---|---|---|
| 2025 | 4.86 | 2.16% |
| 2026 | 4.58 | 5.78% |
| 2027 | 4.31 | 5.90% |
| 2028 | 3.91 | 9.41% |
| 2029 | 3.62 | 7.34% |
| 2030 | 3.07 | 15.17% |
| Current | 4.76 | 13.47% |
|---|---|---|
| 2025 | 4.66 | 2.23% |
| 2026 | 4.39 | 5.78% |
| 2027 | 4.13 | 5.90% |
| 2028 | 3.74 | 9.41% |
| 2029 | 3.47 | 7.34% |
| 2030 | 2.94 | 15.17% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Dec 15 2025 |
| Citigroup |
Buy
➜
Neutral
|
Downgrade | Dec 11 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 02 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
| Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
| Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Dec 15 2025 |
|
Downgrade
Citigroup:
Buy
➜
Neutral
|
Dec 11 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 02 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
|
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
|
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


